Psychedelic Trial Shows 94% Remission RateGilgamesh PharmaceuticalGilgamesh Pharmaceuticals’ GM-2505 achieved a 94% remission rate in a Phase 2a trial for major depressive disorder. The short-acting psychedelic showed significant, sustained improvements and favorable safety in 40 patients.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
